Skip to main content

Advertisement

SpringerLink
Log in

Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis

A retrospective analysis of 106 patients

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

We evaluated the outcomes of patients with different forms of chronic uveitis treated with mycophenolate mofetil (MMF) as an immunomodulatory and steroid-sparing agent. The multi-system side effects that arise after long-term treatment with corticosteroids and other immunosuppressants prompted us to use MMF. MMF is a selective inhibitor of inosine monophosphate dehydrogenase, thus blocking purine synthesis via the de novo pathway preferentially used by T and B lymphocytes.

Methods

Between 1998 and 2003, 106 patients were treated for uveitis (anterior n=26, intermediate n=51, posterior n=23, panuveitis n=6) with MMF at a dose of 1g twice daily. Treatment duration was at least 6 months (n=10), in most cases greater than 12 months (n=77) and in 25 cases between 24 months and 41 months, when the present retrospective evaluation was undertaken. Patient charts were analysed according to a standardized evaluation protocol.

Results

In 95 patients MMF was combined with prednisolone at a dosage of 2.5–10 mg per day. In 8 patients MMF was used as a monotherapy, and in 3 cases one further systemic immunosuppressant was required. The number of recurrences during MMF treatment was none or one in 92 patients, two in 6 cases and three or more in 8 patients. In none of the patients had MMF been stopped at the time of data analysis. The most frequently observed side effects were gastrointestinal upset (15%), followed by headache (9.3%), fatigue (5.7%), eczema (5%), and hair loss (3.5%). Other side effects were sporadic. Most of these phenomena were transitory. Forty-two patients experienced no side effects at all. In 4 patients MMF was judged ineffective due to failure to reduce the number of recurrences of severe inflammation compared with the previous therapeutic regime, or indeed occurrence of persistent macular oedema.

Conclusions

Our results show that MMF is an effective immunosuppressant in patients with uveitis. We provide evidence that MMF controls the disease in the majority of patients with an acceptable profile of side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Adu D, Cross J, Jayne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203–208

    Article  PubMed  CAS  Google Scholar 

  2. Allison AC, Eugui EM (1993) Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136:5–28

    Article  PubMed  CAS  Google Scholar 

  3. Allison AC, Eugui EM (1994) Mycophenolate mofetil (RS-61443): mode of action and effects on graft rejection. In: Thompson AW, Starzl TE (eds) Immunosuppressive drugs: developments in anti-rejection therapy. Arnold, London, pp 141–159

    Google Scholar 

  4. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS (2003) Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110:1061–1065

    Article  PubMed  Google Scholar 

  5. Benez A, Fierlbeck G (2001) Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 144:638–639

    Article  PubMed  CAS  Google Scholar 

  6. Böhm M, Beissert S, Schwarz T et al (1997) Bullous pemphigoid treated with mycophenolate mofetil. Lancet 349:541

    Article  PubMed  Google Scholar 

  7. Bom S, Zamiri P, Lightman S (2001) Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 9:35–40

    Article  PubMed  CAS  Google Scholar 

  8. Chanaud MP, Vistica BP, Eugin E et al (1995) Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res 61:429–434

    Article  PubMed  CAS  Google Scholar 

  9. Deray G, Benhmida M, Le Hoang P et al (1992) Renal function and blood pressure in patients receiving long-term, low-dose cyclosporin therapy for idiopathic autoimmune uveitis. Ann Intern Med 117:578–583

    PubMed  CAS  Google Scholar 

  10. Enk AH, Knop J (1997) Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 350:494

    Article  PubMed  CAS  Google Scholar 

  11. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345:1321–1325

    Google Scholar 

  12. Goldblum R (1993) Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 11(Suppl 8):S117–S119

    PubMed  Google Scholar 

  13. Greiner K, Varikkara M, Santiago C, Forrester JV (2002) Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe 99:691–694

    Article  PubMed  CAS  Google Scholar 

  14. Kilmartin DJ, Forrester JV, Dick AD (1998) Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 352:35–36

    Article  PubMed  CAS  Google Scholar 

  15. Larkin G, Lightman S (1999) Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 218:222–228

    Google Scholar 

  16. Lau CH, Comer M, Lightman S (2003) Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol 31:487–491

    Article  Google Scholar 

  17. Lightman S (1996) New therapeutic options in uveitis. Eye 11:222–226

    Google Scholar 

  18. Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357–1359

    Article  PubMed  CAS  Google Scholar 

  19. Meihsler W, Reinisch W, Moser G et al (2001) Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 96:782–787

    Article  PubMed  Google Scholar 

  20. Mochizuki M, Masuda K, Sakane T et al (1993) A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115:763–769

    PubMed  CAS  Google Scholar 

  21. Nowack R, Gobel U, Klooker P et al (1999) Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10:1965–1971

    PubMed  CAS  Google Scholar 

  22. Nussenblatt RB, Palestine AG, Chan CC et al (1991) Randomised, double-masked study of cyclosporin compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 112:138–146

    PubMed  CAS  Google Scholar 

  23. Pirsch J, Bekersky I, Vincenti F et al (2000) Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 40:527–532

    Article  PubMed  CAS  Google Scholar 

  24. Rigotti P, Cadrobbi R, Baldan N et al (2000) Mycophenolate mofetil (MMF) versus azathioprine (AZA) in pancreas transplantation: a single-center experience. Clin Nephrol 53:52–54

    PubMed  CAS  Google Scholar 

  25. Sarwal MM, Yorgin PD, Alexander S et al (2001) Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 72:13–21

    Article  PubMed  CAS  Google Scholar 

  26. Sollinger HW (1995) US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225–232

    Article  PubMed  CAS  Google Scholar 

  27. Spatz S, Rudnicka A, McDonald CJ (1978) Mycophenolic acid in psoriasis. Br J Dermatol 98:429–435

    Article  PubMed  CAS  Google Scholar 

  28. Tricontinental Mycophenolate mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadveric renal transplantation. Transplantation 61:1029–1037

    Article  Google Scholar 

  29. Young CJ, Sollinger HW (1994) Mycophenolate mofetil (RS-61443). In: Kupiec-Weglinski JW (ed) New immunosuppressive modalities in organ transplantation. Landes, Austin, TX, pp 1–17

    Google Scholar 

  30. Zierhut M, Stübiger N, Aboalchamat W et al (2001) Immunosuppressive treatment with mycophenolate mofetil (CellCept) in the therapy of uveitis. Ophthalmologe 98:647–651

    Article  PubMed  CAS  Google Scholar 

  31. Zimmer-Molsberger B, Knauf W, Thiel E (1997) Mycophenolate mofetil for severe autoimmune haemolytic anaemia. Lancet 350:1003–1004

    Article  PubMed  CAS  Google Scholar 

  32. Zurdel J, Aboalchamat B, Zierhut M et al (2001) Erste klinische Erfahrungen mit Mycophenolat mofetil bei der immunsuppressiven Therapie des okulären Pemphigoids. Klin Monatsbl Augenheilkd 218:222–228

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology I, University Eye Hospital, Schleichstrasse 12, 72076, Tübingen, Germany

    Kirsten Siepmann, Matthias Huber, Nicole Stübiger, Christoph Deuter & Manfred Zierhut

Authors
  1. Kirsten Siepmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicole Stübiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christoph Deuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manfred Zierhut
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Zierhut.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siepmann, K., Huber, M., Stübiger, N. et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis. Graefe's Arch Clin Exp Ophthalmo 244, 788–794 (2006). https://doi.org/10.1007/s00417-005-0066-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-005-0066-8

Keywords

Search

Navigation